

## 1. Fund Manager's Commentary

The Girik Multicap Growth Equity Strategy is inspired by the CANSLIM philosophy of stock picking developed by American investor William J. O'Neil. The goal of this strategy is to identify leading companies from leading industry groups that show sharp acceleration in earnings, newness in products or change in management and suggests buying them at the right price with enough margin of safety ahead of the company's major stock price advance.

In these uncertain times, where macroeconomic factors continue to dominate the market narrative, volatility is likely to persist. At Girik, we remain focused on what we can control - building a portfolio of high-quality companies in leading sectors.

We believe stock prices are ultimately a slave to earnings. Our investment approach centers on identifying businesses with **accelerating earnings**, an indicator we consider reliable for anticipating potential stock outperformance. We deliberately focus on industry leaders because laggards, no matter how inexpensive they may appear, seldom deliver sustainable returns. We also strive to avoid valuation traps. A low P/E ratio doesn't necessarily mean a stock is cheap, just as a high P/E doesn't automatically imply it's expensive. What truly matters is whether the valuation is supported by a rapidly growing business with healthy cash flows and a strong balance sheet. When these fundamentals are in place, premium valuations can be both justified and sustained.

The table on the following page outlines key performance metrics of our portfolio companies for the quarter ended March 2025 reflecting strong underlying growth. While short-term price movements may remain erratic amid current uncertainty, we believe that over the medium to long term, strong business fundamentals will ultimately be reflected in stock price performance.

In aggregate, our portfolio companies delivered EPS growth of ~15% for FY25. The expected EPS growth of our portfolio over the next 2 years (FY25 to FY27) is ~23%.

The portfolio is highly liquid, with a healthy mix of high efficiency, fast growing, large, mid and small cap businesses. True to our style, over the last 12 months, we have tried to navigate choppy markets and focused on risk management (and minimising drawdowns) by cutting losers and adding to our existing winners. We have also added some emerging leaders that display strong earnings acceleration, along with an element of "Newness".

## 1. Fund Manager's Commentary (contd...)

| Q4 FY25 KEY METRICS FOR PORTFOLIO COMPANIES    |                       |               |               |                  |                |                    |
|--|-----------------------|---------------|---------------|------------------|----------------|--------------------|
| Company  | Consolidated / Parent | Revenue / Nil | EBITDA / PPoP | Profit after tax | P/E Ratio FY25 | P/E Ratio FY26 (E) |
|  |                       | YoY%          | YoY%          | YoY%             |                |                    |
| Eureka Forbes Ltd                              | Consolidated          | 10.68%        | 44.65%        | 131.31%          | 63.79x         | 61.74x             |
| Bharti Airtel Ltd                              | Consolidated          | 15.33%        | 21.84%        | 88.32%           | 29.96x         | 33.34x             |
| Indiamart InterMesh Ltd                        | Consolidated          | 12.70%        | 47.73%        | 81.00%           | 22.54x         | 23.98x             |
| Awfis Space Solutions Ltd                      | Consolidated          | 46.22%        | 72.72%        | 65.95%           | 38.86x         | 27.04x             |
| Interglobe Aviation Ltd                        | Consolidated          | 24.27%        | 52.48%        | 61.89%           | 27.23x         | 27.76x             |
| Quesst Corp Ltd                                | Consolidated          | 3.38%         | 12.57%        | 48.66%           | 46.14x         | 18.63x             |
| Concord Biotech Ltd                            | Consolidated          | 34.77%        | 41.80%        | 47.75%           | 47.31x         | 41.70x             |
| Hikal Ltd                                      | Consolidated          | 7.47%         | 31.28%        | 47.65%           | 53.98x         | 40.02x             |
| MPS Ltd  | Consolidated          | 21.89%        | 30.84%        | 43.55%           | 34.08x         | 28.25x             |
| Muthoot Finance Ltd                            | Parent                | 36.02%        | 42.25%        | 42.80%           | 17.74x         | 13.74x             |
| Elecon Engineering Company Ltd                 | Consolidated          | 41.15%        | 43.60%        | 40.77%           | 24.28x         | 32.71x             |
| India Shelter Finance Corporation Ltd          | Consolidated          | 26.72%        | 36.19%        | 38.46%           | 23.66x         | 19.64x             |
| Hindustan Petroleum Corporation Ltd            | Consolidated          | -4.40%        | 18.71%        | 26.08%           | 11.44x         | 12.65x             |
| Entero Healthcare Solutions Ltd                | Consolidated          | 29.48%        | 69.39%        | 22.51%           | 52.17x         | 33.83x             |
| Reliance Industries Ltd                        | Consolidated          | 11.85%        | 3.10%         | 18.38%           | 24.76x         | 23.68x             |
| Five-Star Business Finance Ltd                 | Consolidated          | 21.26%        | 18.92%        | 18.22%           | 19.87x         | 16.61x             |
| Larsen & Toubro Ltd                            | Consolidated          | 10.90%        | 13.39%        | 17.08%           | 32.98x         | 29.26x             |
| Bajaj Finance Ltd                              | Parent                | 21.39%        | 23.29%        | 15.85%           | 29.49x         | 27.74x             |
| International Gemmological Institute India Ltd | Consolidated          | 9.62%         | 12.83%        | 11.62%           | 32.97x         | 27.74x             |
| Ultratech Cement Ltd                           | Consolidated          | 12.95%        | 12.01%        | 9.56%            | 56.17x         | 35.67x             |
| HDFC Bank Ltd                                  | Parent                | 10.28%        | -9.35%        | 6.69%            | 18.14x         | 17.53x             |
| 360 One WAM Ltd                                | Consolidated          | 13.79%        | 16.48%        | 3.73%            | 37.50x         | 33.06x             |
| Mankind Pharma Ltd                             | Consolidated          | 26.15%        | 15.58%        | -9.79%           | 50.36x         | 52.35x             |
| State Bank Of India                            | Parent                | 2.69%         | 8.83%         | -9.93%           | 6.70x          | 6.86x              |
| Medi Assist Healthcare Services Ltd            | Consolidated          | 13.24%        | 10.08%        | -13.82%          | 35.04x         | 36.15x             |
| Eternal Ltd                                    | Consolidated          | 59.77%        | 17.00%        | N/M              | 347.14x        | 238.31x            |
| UPL Ltd  | Consolidated          | 7.49%         | 65.17%        | N/M              | 45.45x         | 20.19x             |

Source: Bloomberg & Internal Research

Note: For Financials revenue is considered as Net Interest Income, except for 360 One WAM Ltd; N/M = Not Meaningful